1-(1-phenyl-1H-pyrazolo[3,4-b]quinoxalin-3-yl)-ethane-1,2-diol | 68787-23-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-(1-phenyl-1H-pyrazolo[3,4-b]quinoxalin-3-yl)-ethane-1,2-diol
• 英文别名: 1-(1-phenyl-1H-pyrazolo[3,4-b]quinoxalin-3-yl)-ethane-1,2-diol；(R)-1-(1-phenyl-1H-pyrazolo[3,4-b]quinoxalin-3-yl)-ethane-1,2-diol；(R)-1-(1-Phenyl-1H-pyrazolo[3,4-b]chinoxalin-3-yl)-aethan-1,2-diol
• CAS: 68787-23-5
• 化学式: C₁₇H₁₄N₄O₂
• 分子量: 306.324
• InChiKey: OVJDURNHVALGIS-AWEZNQCLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.99
• 重原子数：
  23.0
• 可旋转键数：
  3.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  84.06
• 氢给体数：
  2.0
• 氢受体数：
  6.0

反应信息

• 作为产物：
  描述：

  L-阿拉伯糖 、 苯肼,盐酸盐 、 邻苯二胺 在 溶剂黄146 作用下， 生成 1-(1-phenyl-1H-pyrazolo[3,4-b]quinoxalin-3-yl)-ethane-1,2-diol
  参考文献：
  名称：

  Courtois; Ariyoshi, Annales Pharmaceutiques Francaises, 1958, vol. 16, p. 385,391

  摘要：

  DOI：

文献信息

• Acute Renal Failure After Cardiopulmonary Bypass: A Possible Association With Drugs of the Fibrate Group
  作者：Kamel M. Sharobeem、Brendan P. Madden、Russell Millner、Lindsey M. Rolfe、Carol A. Seymour、John Parker

  DOI：10.1177/107424840000500105

  日期：2000.3

  Background: Renal failure is a recognized, but infrequent, complication following cardiac surgery. The causes for this condition are multifactorial, and a major concern is that the occurrence of postoperative acute renal failure is still associated with a high mortality rate.

  Methods and Materials: We report unexpected acute renal failure occurring in 4 patients after uncomplicated cardiac surgery. Each patient was taking a fibric acid derivative at the time of surgery. Renal failure occurred rapidly within 3 days of surgery and was associated with increased concentrations of skeletal muscle-derived creatine kinase (CK). One patient devel oped myoglobinuria, and another developed a malignant hyperthermia-like syndrome.

  Conclusions: These cases show that patients receiving lipid lowering medications could be at higher risk of developing acute renal failure after cardiac surgery. This association merits careful evaluation in large prospective studies and, if proved, would suggest that patients taking either statins or fibrates should discontinue doing so before cardiac surgery.

  背景：肾衰竭是心脏手术后的一个公认但不常见的并发症。这种情况的原因是多因素的，一个主要关注点是术后急性肾衰竭的发生仍然与较高的死亡率相关。 方法和材料：我们报告了4例在心脏手术后发生意外急性肾衰竭的患者。每位患者在手术时正在服用一种纤维酸衍生物。肾衰竭在手术后3天内迅速发生，并伴随着骨骼肌源性肌酸激酶（CK）浓度的增加。一名患者出现了肌红蛋白尿症，另一名患者出现了恶性高热综合征。 结论：这些病例表明，接受降脂药物治疗的患者在心脏手术后发展急性肾衰竭的风险可能更高。这种关联需要在大规模前瞻性研究中进行仔细评估，如果证实，将建议在心脏手术前服用他汀类药物或纤维酸衍生物的患者应停止服用。
• Ohle; Liebig, Chemische Berichte, vol. 75>1942>1536, p. 1537,1539
  作者：Ohle、Liebig

  DOI：——

  日期：——